Real-world performance of the first approved plasma biomarker test for Alzheimer disease pathology, focusing on the rate of false-positive results in clinical use.
The study found that the approved plasma Alzheimer disease test may produce a substantial number of false-positive results when used in real-world settings, though specific numeric rates are not provided in the abstract.
This is a Medical News summary article, not the primary research; full methodology, sample size, and quantitative results of the underlying JAMA Neurology study are not detailed in the abstract.
Clinicians using the first approved plasma Alzheimer biomarker test should be aware of the potential for false positives in real-world practice, and confirmatory testing or clinical correlation may be warranted before acting on results.
Explore related topics
